Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)

NCT04851873 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Spinal Muscular Atrophy

Interventions

GENETIC: OAV101

Sponsor

Novartis Pharmaceuticals